ATE177645T1 - Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält - Google Patents

Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält

Info

Publication number
ATE177645T1
ATE177645T1 AT93902088T AT93902088T ATE177645T1 AT E177645 T1 ATE177645 T1 AT E177645T1 AT 93902088 T AT93902088 T AT 93902088T AT 93902088 T AT93902088 T AT 93902088T AT E177645 T1 ATE177645 T1 AT E177645T1
Authority
AT
Austria
Prior art keywords
growth hormone
asparagine
pharmaceutical formulation
formulation containing
containing growth
Prior art date
Application number
AT93902088T
Other languages
English (en)
Inventor
Hans Holmegaard Sorensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE177645T1 publication Critical patent/ATE177645T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93902088T 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält ATE177645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
ATE177645T1 true ATE177645T1 (de) 1999-04-15

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902088T ATE177645T1 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält

Country Status (19)

Country Link
US (2) US5977069A (de)
EP (1) EP0618806B1 (de)
JP (1) JP3662580B2 (de)
KR (1) KR100270726B1 (de)
AT (1) ATE177645T1 (de)
AU (1) AU664416B2 (de)
BG (1) BG98804A (de)
CA (1) CA2125856A1 (de)
CZ (1) CZ282826B6 (de)
DE (1) DE69228704T2 (de)
DK (1) DK204791D0 (de)
FI (1) FI942905A7 (de)
HU (1) HUT69682A (de)
NO (1) NO942299L (de)
NZ (1) NZ246555A (de)
RO (1) RO112086B1 (de)
RU (1) RU2098130C1 (de)
SK (1) SK73794A3 (de)
WO (1) WO1993012811A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
JPH10511964A (ja) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
SK281571B6 (sk) * 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0303746B2 (de) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisierung von Wachstumshormonen
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
KR100270726B1 (ko) 2000-11-01
SK73794A3 (en) 1995-03-08
NO942299D0 (no) 1994-06-17
KR940703689A (ko) 1994-12-12
RO112086B1 (ro) 1997-05-30
JP3662580B2 (ja) 2005-06-22
NZ246555A (en) 1996-03-26
DK204791D0 (da) 1991-12-20
CA2125856A1 (en) 1993-07-08
RU94045921A (ru) 1996-08-27
CZ282826B6 (cs) 1997-10-15
FI942905L (fi) 1994-06-17
EP0618806B1 (de) 1999-03-17
AU664416B2 (en) 1995-11-16
DE69228704D1 (de) 1999-04-22
US5977069A (en) 1999-11-02
BG98804A (bg) 1995-02-28
FI942905A0 (fi) 1994-06-17
WO1993012811A1 (en) 1993-07-08
JPH07502515A (ja) 1995-03-16
HU9401831D0 (en) 1994-09-28
HUT69682A (en) 1995-09-28
RU2098130C1 (ru) 1997-12-10
DE69228704T2 (de) 1999-09-16
FI942905A7 (fi) 1994-06-17
EP0618806A1 (de) 1994-10-12
AU3344593A (en) 1993-07-28
CZ145894A3 (en) 1994-12-15
NO942299L (no) 1994-06-17
US5851992A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
DE69228704D1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
DE10399015I1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE69401691D1 (de) Parenterale Zubereitungen mit verzögerter Wirkstoffreigabe enthaltend Polyglyceroldiester
DE69525955D1 (de) Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
ATE79619T1 (de) Arzneimittel.
NZ230280A (en) Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu
PT785795E (pt) Composicao farmaceutica
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DK157689A (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
PH27446A (en) Compound with gastric acid inhibitory effect
IL115592A0 (en) Pharmaceutical formulation comprising a growth hormone and leucine
HUP9802286A2 (hu) Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
DE69123190D1 (de) Hirudin enthaltende orale Arzneimittel
DE69211743D1 (de) Aureobasidin enthaltendes Arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties